首页> 美国卫生研究院文献>Frontiers in Cellular and Infection Microbiology >An Experimental Pipeline for Initial Characterization of Bacterial Type III Secretion System Inhibitor Mode of Action Using Enteropathogenic Yersinia
【2h】

An Experimental Pipeline for Initial Characterization of Bacterial Type III Secretion System Inhibitor Mode of Action Using Enteropathogenic Yersinia

机译:使用肠致病性耶尔森氏菌对III型细菌分泌系统抑制剂作用模式进行初步表征的实验管道

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Dozens of Gram negative pathogens use one or more type III secretion systems (T3SS) to disarm host defenses or occupy a beneficial niche during infection of a host organism. While the T3SS represents an attractive drug target and dozens of compounds with T3SS inhibitory activity have been identified, few T3SS inhibitors have been validated and mode of action determined. One issue is the lack of standardized orthogonal assays following high throughput screening. Using a training set of commercially available compounds previously shown to possess T3SS inhibitory activity, we demonstrate the utility of an experiment pipeline comprised of six distinct assays to assess the stages of type III secretion impacted: T3SS gene copy number, T3SS gene expression, T3SS basal body and needle assembly, secretion of cargo through the T3SS, and translocation of T3SS effector proteins into host cells. We used enteropathogenic Yersinia as the workhorse T3SS-expressing model organisms for this experimental pipeline, as Yersinia is sensitive to all T3SS inhibitors we tested, including those active against other T3SS-expressing pathogens. We find that this experimental pipeline is capable of rapidly distinguishing between T3SS inhibitors that interrupt the process of type III secretion at different points in T3SS assembly and function. For example, our data suggests that Compound 3, a malic diamide, blocks either activity of the assembled T3SS or alters the structure of the T3SS in a way that blocks T3SS cargo secretion but not antibody recognition of the T3SS needle. In contrast, our data predicts that Compound 4, a haloid-containing sulfonamidobenzamide, disrupts T3SS needle subunit secretion or assembly. Furthermore, we suggest that misregulation of copy number control of the pYV virulence plasmid, which encodes the Yersinia T3SS, should be considered as a possible mode of action for compounds with T3SS inhibitory activity against Yersinia.
机译:数十种革兰氏阴性病原体使用一种或多种III型分泌系统(T3SS)解除宿主防御能力,或在感染宿主生物时占据有利位置。尽管T3SS代表了有吸引力的药物靶标,并且已鉴定出数十种具有T3SS抑制活性的化合物,但很少有T3SS抑制剂得到验证并确定了作用方式。一个问题是高通量筛选后缺乏标准化的正交测定。使用一组先前证明具有T3SS抑制活性的可商购化合物的训练,我们证明了由六个不同测定组成的实验管道的实用性,可用来评估受影响的III型分泌阶段:T3SS基因拷贝数,T3SS基因表达,T3SS基础机体和针头装配,通过T3SS分泌货物,并将T3SS效应蛋白转运到宿主细胞中。我们将肠致病性耶尔森氏菌用作表达T3SS的模型生物,因为耶尔森氏菌对我们测试的所有T3SS抑制剂均敏感,包括那些对表达T3SS的其他病原体具有活性的抑制剂。我们发现该实验管道能够快速区分T3SS抑制剂,这些抑制剂会中断T3SS组装和功能中不同点的III型分泌过程。例如,我们的数据表明,化合物3(一种苹果酸二酰胺)会阻止组装的T3SS的活性或改变T3SS的结构,从而阻止T3SS货物的分泌,但不会阻止T3SS针的抗体识别。相反,我们的数据预测化合物4(一种含卤素的磺酰胺基苯甲酰胺)会破坏T3SS针的亚基分泌或组装。此外,我们建议应将编码Yersinia T3SS的pYV毒力质粒的拷贝数控制失调视为对Ters抑制T3SS活性的化合物的一种可能的作用方式。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号